

Add-on effect of Guizhi Fuling formula to mifepristone for endometriosis

A meta-analysis of randomized controlled trials

Wenbin Meng, MM, Na Ta, MM, Fei Wang, MM*

Abstract

Background: Guizhi Fuling pill, a famous traditional Chinese herbal formula, has been widely used for treatment of gynecological diseases. This meta-analysis sought to evaluate the add-on effect of Guizhi Fuling capsule (GZFL) to mifepristone in women with endometriosis.

Methods: A comprehensively literature search was conducted using Pubed, Embase, Cochrane Library, Wanfang, CNKI, VIP databases from their inceptions to January 25, 2019. Randomized controlled trials that compared GZFL plus mifepristone to mifepristone alone for treatment of endometriosis were eligible. Main outcomes were pregnancy, reduction of the recurrence, and serum level of follicle-stimulating hormone, luteinizing hormone, estradiol or progesterone.

Results: A total of 1052 women with endometriosis from 10 trials were identified and analyzed. Meta-analyses showed that GZFL plus mifepristone was superior to mifepristone in reducing the recurrence of endometriosis (RR 0.40; 95% CI 0.27–0.59) and improving the pregnancy (risk ratio [RR] 1.74; 95% confidence intervals [CI] 1.40–2.17). Moreover, adjuvant treatment with GZFL also significantly reduced serum level of estradiol (mean difference [MD] –20.83 pmol/L; 95% CI –34.01 to –7.65) and progesterone (MD –0.18 mmol/L; 95% CI –0.23 to –0.12). However, there were no significant differences in serum level of follicle-stimulating hormone (MD –0.42 U/L; 95% CI –1.16 to 0.31) and luteinizing hormone (MD –0.04 U/L; 95% CI –0.43 to 0.34).

Conclusion: GZFL as adjuvant therapy to mifepristone appears to have additional benefits in preventing recurrence of endometriosis and improving pregnancy among women with endometriosis. However, these conclusions should be *interpreted* with caution due to the methodological flaws of the included trials.

Abbreviations: CI = confidence intervals, FSH = follicle-stimulating hormone, GZFL = Guizhi Fuling capsule, MD = mean difference, RCT = randomized controlled trials, RR = risk ratio, TCM = Traditional Chinese Medicine.

Keywords: endometriosis, guizhi fuling capsule, meta-analysis, mifepristone, randomized controlled trials

1. Introduction

Endometriosis is a gynecological condition characterized by the presence of endometrial tissue outside the uterus. Approximately 10% to 15% women during reproductive ages suffer from endometriosis across worldwide.^[1,2] The common symptoms of endometriosis include pelvic pain, dysmenorrhea, fatigue, dyspareunia, and infertility. Women with endometriosis have an increased risk of ovarian cancer or endometriosis-associated adenocarcinoma.^[3] Current therapeutic choices for endometri-

Editor: Muhammad Shahzad Aslam.

The authors have no funding and conflicts of interest to disclose.

Department of Obstetrics and Gynecology, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

^{*} Correspondence: Fei Wang, Department of Obstetrics and Gynecology, The Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Road, Hohhot, China (e-mail: wangfei198008@163.com).

Medicine (2019) 98:33(e16878)

Received: 18 February 2019 / Received in final form: 16 July 2019 / Accepted: 17 July 2019

http://dx.doi.org/10.1097/MD.000000000016878

osis mainly include medication and surgical approach.^[4] Unfortunately, higher recurrence rate post-surgical procedure remains a big challenge.^[5,6] Therefore, it is warranted to seek new therapy for better management of endometriosis.

Traditional Chinese Medicine (TCM) has been widely applied to manage the gynecological diseases including endometriosis.^[7] Guizhi Fuling Pill was firstly recorded in Jingui Yaolue of the Han dynasty. This formula consists of Ramulus Cinnamomi, Semen Persicae, Radix Paeoniae Alba, Poria, and Cortex Moutan. Based on TCM theory, Guizhi Fuling formula possesses the effects of activating blood and dissolving blood stasis. Guizhi Fuling Capsule (GZFL) is a compound Chinese medicine preparation refined by modern technology. Mifepristone, a progesterone antagonist, has been introduced for the treatment of endometriosis for decades.^[8-11] GZFL alone or in combination with mifepristone have been widely used for management of endometriosis.^[12,13] To date, no previous meta-analysis has been evaluated the add-on effect of GZFL in endometriosis. We therefore performed this meta-analysis of randomized controlled trials (RCT) to evaluate the effect of GZFL add-on therapy to mifepristone in patients with endometriosis.

2. Materials and methods

2.1. Literature search

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^[14]

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

A comprehensively literature search was conducted using Pubmed, Embase, Cochrane Library, Wanfang, CNKI, VIP databases from their inceptions to January 25, 2019 without language restriction. Searched keywords included "Guizhi Fuling" OR "Gyejibokryeong-Hwan" AND mifepristone" OR "RU-486" AND "endometriosis" AND ("random" OR "randomized controlled trial". Furthermore, reference lists of all pertinent articles were manually reviewed to identify any additional studies. Ethical approval was not required because this study only analyzed the existing literature.

2.2. Study selection

Inclusion criteria were as follows:

- 1. RCT as study design;
- 2. participants were women with confirmed endometriosis;
- 3. GZFL formula (pill, capsule, decoction, or tablet) plus mifepristone versus mifepristone alone as intervention; and
- 4. outcome measures were pregnancy rate and recurrence of endometriosis.

Secondary outcomes were serum level of follicle-stimulating hormone (FSH), luteinizing hormone, estradiol or progesterone, and adverse events including irregular vaginal bleeding, gastrointestinal reaction, hot flashes or abnormal liver function. Exclusion criteria were:

- 1. non-randomized trials and suspected plagiarism;
- 2. modified Guizhi Fuling formula as intervention;
- 3. any different interventions except for GZFL; and
- 4. outcome measures were not of interests.

2.3. Data extraction and quality assessment

For each included trial, the following information was collected by two authors independently: first author's name, publication year, study design, duration of disease, sample sizes, mean age or range, dosage of GZFL and mifepristone, course of treatment, outcome measures, follow-up duration, and drug-related adverse events. The risk of bias tool of the Cochrane Handbook for Systematic Reviews of Interventions was used to evaluate the methodological quality of included trials, which assessing sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. Disagreements in data extraction and quality assessment between two reviewers were resolved by consensus.

2.4. Statistical analysis

Pooled estimates were express by risk ratios (RR) with 95% confidence interval (CI) for binary variables. Estimates of




Figure 1. Flow chart of trials selection process.

continuous variables were pooled as the mean difference (MD) with 95% CI. The magnitude of heterogeneity across trials was examined using the Cochrane Q test and I^2 index. A fixed-effect model meta-analysis was applied in the absence of substantial heterogeneity (*P* value of Cochrane Q test >0.10 or I^2 index <50%). Otherwise, we selected a random effect model for pooling data. Sensitivity analysis was conducted by removing each study in turn from the meta-analysis to check the robustness of the pooling results. Subgroup analyses were performed by the length of treatment (3 months vs 6 months). Publication bias was scheduled using the Begg rank correlation test^[15] and Egger regression test.^[16] Meta-analysis was conducted using Review Manager 5.1 software (The Cochrane Collaboration, Copenhagen, Denmark) and STATA 12.0 (STATA Corp LP, College Station, TX).

3. Results

3.1. Search results and study characteristics

Our initial literature searches produced 233 records. A total of 176 records left after removal of duplicates. Of which, 138 were removed after scanning the titles and abstracts. Thirty-eight full-text articles were retrieved for detailed assessment. Twenty-eight articles were further excluded for various reasons (Fig. 1). Thus, 10 trials^[17–26] were finally included in the current meta-analysis.

Table 1 summarizes the main characteristics of the included trials. All the included trials were conducted in China and published between 2007 and 2018. The included trials recruited a total of 1052 patients with endometriosis, with sample sizes ranging from 64 to 156. In most trials, GZFL was administrated orally 0.93 g at one time, 3 times per day. Clinically, 3 to 6 months duration of GZFL treatment is recommended. Table 2 shows the overview ingredients of GZFL. The methodological quality of included trials is summarized in Figure 2. Two trials^[20,21] described the definition of recurrence of endometriosis, but others did not clearly define the recurrence. Based on the items of the methodological reporting, most of the trials were grouped as suboptimal methodological quality with unclear risk of bias. All the included trials did not consider TCM syndrome differentiation at the enrolment of patients.

3.2. Pregnancy rate and recurrence rate

Eight trials^[17–23,25] reported pregnancy rate during up to 24-month of follow-up. As shown in Figure 3A, a fixed effect model was selected because no obvious heterogeneity was observed ($I^2 = 0\%$, P = .86). The pooled RR was 1.74 (95% CI 1.40 to 2.17) comparing GZFL plus mifepristone to mifepristone alone treatment. There was no evidence of publication bias according to the results of Begg test (P = .536) and Egger test (P = .573). Recurrence of endometriosis was assessed in 5 trials.^[19–21,23,25] As shown in Figure 3B, we used a fixed-effect model due to no evidence of obvious heterogeneity ($I^2 = 0\%$, P = .99). Meta-analyses indicated that GZFL plus mifepristone was superior to mifepristone alone in reducing the recurrence (RR 0.40; 95% CI 0.27–0.59).

3.3. Serum level Of FSH, luteinizing hormone, estradiol, and progesterone

Four trials^[18,22,24,26] provide serum level of hormone, including FSH, luteinizing hormone, estradiol, and progesterone. As shown in Figure 4, the pooled results showed that GZFL plus


3

able

Eiret author/woor	Cample cize	Ano (work)	Eiret authar(voar Camula ciza Aza (voava) Duvation of discover	Main internetione	auontion o	Course of treatment	Eollow-up duration	Outoomo mootiiloo
rust aution/year	odilipic size	Age (Jeans)	Duration of uiscase				runuw-up uuratiun	
				den E Broch				
Lu CH 2007 ⁽¹⁷⁾	GZH_:40	GZFL: 24-42	GZFL: 10 m-13y	GZFL capsule + Mifepristone 8.3	Mifepristone 8.3 mg/d	3 months	3 months	(1)+(7)
	Con: 40	Con: 25-44	Con: 1–12 y	mg/d)
Lin TY 2010 ^[18]	GZH.:32	GZFL: 27-47	GZRL: 2.5–8 y	GZFL capsule + Mifepristone 10	Mifepristone 10 mg/d	3 months	6 months	(1)+(3)+(4)+(5)+(6)+(7)
	Con:32	Con: 25-45	Con: 3–9 y	mg/d))))))
Pan XR 2011 ^[19]	GZFL:44	24-43	3 m-12y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d	6 months	24 months	(1)+(2)+(7)
	Con:41			12.5 mg/d)))
Gu ZY 2012 ^[20]	GZFL:78	GZFL: 24-44	GZFL: 5 m–10 y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d	6 months	18 months	(1)+(2)+(7)
	Con:78	Con: 25–42	Con: 10 m–8 y	12.5 mg/d))
Gao Z 2012 ^[21]	GZFL:74	GZFL: 21-43	GZFL: 1–12 y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d+ Laparo-	6 months	6-12 months	(1)+(2)
	Con:73	Con: 19-44	Con: 11 m-13 y	12.5 mg/d+ Laparoscopy	scopy)
Shen WL 2013 ^[22]	GZH.:50	GZFL: 32 ± 7	GZFL: 2.6±1.8y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d	3 months	24 months	(1)+(5)+(6)
	Con: 50	Con: 33±5	Con: 2.7 ± 2.0 y	12.5 mg/d)))
Hao CR 2015 ^[23]	GZFL:61	33.0 ± 5.8	1.5–13 y	GZFL capsule + Mifepristone 10	Mifepristone 10 mg/d + Laparo-	3 months	24 months	(1)+(2)+(7)
	Con:61			mg/d+ Laparoscopy	scopy)))
Yang CQ 2015 ^[24]	GZH.:55	32 ± 5	5.3±2.7 y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d	3 months	6 months	(3)+(4)+(5)+(6)+(7)
	Con: 55			12.5 mg/d)))
Wang JY 2017 ^[25]	GZFL:46	GZFL: 33.4±2.3	GZFL: 5.2±1.1 y	GZFL capsule + Mifepristone 25	Mifepristone 25 mg/d	3 months	12 months	(1)+(2)+(7)
	Con: 46	Con: 34.1 ± 1.8	Con: 5.4 ± 0.8 y	mg/d)
Lv YL 2017 ^[26]	GZH.:48	$GZFL: 28.5 \pm 4.9$	GZFL: 2.6±0.9 y	GZFL capsule + Mifepristone	Mifepristone 12.5 mg/d	3 months	6 months	(3)+(4)+(5)+(6)+(7)
	Con: 48	Con: 29.1±4.3	Con: 2.9 ± 0.8 y	12.5 mg/d)))
Con=control, GZFL=-	Guizhi Fuling; (1)pregn	iancy rate; (2)recurrend	ce rate; (3)follicle-stimulating	hormone; (4)luteinizing hormone; (5)estr	Con = control, GZFL = Guizhi Fuling; (1)pregnancy rate; (2)recurrence rate; (3)follicle-stimulating hormone; (5)estradiol; (6)progesterone; (7)adverse events.	ö		

Table O

Chinese name	English name	Latin name	Genus	Family	Proportion
Guìzhī	Cassia Twig	Ramulus Cinnamomi	Cinnamomum	Lauraceae	1
Táo rén	Peach Seed	Semen Persicae	Prunus	Rosaceae	1
Bái Sháo	White Paeony Root	Radix Paeoniae Alba	Cynanchum	Apocynaceae	1
Báifúlíng	White Poria cocos	Poria Cocos	Smilax	Smilaceae	1
D⊠npí	Tree Peony Bark	Cortex Moutan	Paeonia	Paeoniaceae	1





	GZFI	_	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Lu CH	4	9	2	10	2.4%	2.22 [0.53, 9.37]	2007	
Lin TY	10	18	11	23	12.2%	1.16 [0.64, 2.10]	2010	
Pan XR	5	11	2	9	2.8%	2.05 [0.51, 8.16]	2011	
Gu ZY	36	78	21	78	26.6%	1.71 [1.11, 2.65]	2012	
Gao Z	36	74	19	73	24.2%	1.87 [1.19, 2.94]	2012	
Shen WL	23	50	10	50	12.7%	2.30 [1.22, 4.32]	2013	
Hao CR	17	26	10	22	13.7%	1.44 [0.84, 2.46]	2015	+
Wang JY	8	17	4	15	5.4%	1.76 [0.66, 4.70]	2017	
Total (95% CI)		283		280	100.0%	1.74 [1.40, 2.17]		+
Total events	139		79					1000
Heterogeneity: Chi ² = Test for overall effect	Z= 4.95			- 0 /0				0.05 0.2 1 5 Favours Control Favours GZFL
	Z= 4.95	P < 0.0	00001)			Risk Ratio		
Test for overall effect	Z = 4.95 (e GZFI	(P < 0.0	Contr	ol	Weight	Risk Ratio M-H, Fixed, 95% Cl	Year	Favours Control Favours GZFL
Test for overall effect B Recurrence rat	Z = 4.95 (e GZFI	(P < 0.0	Contr	ol	Weight 18.5%			Favours Control Favours GZFL Risk Ratio
Test for overall effect B Recurrence rat	Z = 4.95 e GZFI Events	P < 0.0	Contr Events	ol Total		M-H, Fixed, 95% Cl	2011	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rat Study or Subgroup Pan XR	Z = 4.95 e GZFI Events 6	P < 0.0 Total 44	Contr Events 13	ol <u>Total</u> 41	18.5%	M-H, Fixed, 95% Cl 0.43 [0.18, 1.03]	2011 2012	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rat Study or Subgroup Pan XR Gao Z	Z = 4.95 e <u>GZFI</u> <u>Events</u> 6 11	P < 0.0 Total 44 74	00001) Contr Events 13 27	ol <u>Total</u> 41 73	18.5% 37.4%	M-H, Fixed, 95% Cl 0.43 [0.18, 1.03] 0.40 [0.22, 0.75]	2011 2012 2012	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rat Study or Subgroup Pan XR Gao Z Gu ZY	Z = 4.95 (e <u>GZFI</u> <u>Events</u> 6 11 7	P < 0.0 <u>Total</u> 44 74 78	Contr Events 13 27 18	ol <u>Total</u> 41 73 78	18.5% 37.4% 24.8%	M-H, Fixed, 95% Cl 0.43 [0.18, 1.03] 0.40 [0.22, 0.75] 0.39 [0.17, 0.88]	2011 2012 2012 2012 2015	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rate Study or Subgroup Pan XR Gao Z Gu ZY Hao CR	z = 4.95 (e <u>GZFI</u> <u>Events</u> 6 11 7 2	P < 0.0 Total 44 74 78 61	Contr Events 13 27 18 7	ol <u>Total</u> 41 73 78 61 46	18.5% 37.4% 24.8% 9.6%	M-H, Fixed, 95% Cl 0.43 [0.18, 1.03] 0.40 [0.22, 0.75] 0.39 [0.17, 0.88] 0.29 [0.06, 1.32]	2011 2012 2012 2012 2015	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rat Study or Subgroup Pan XR Gao Z Gu ZY Hao CR Wang JY	z = 4.95 (e <u>GZFI</u> <u>Events</u> 6 11 7 2	P < 0.0 <u>Total</u> 44 74 78 61 46	Contr Events 13 27 18 7	ol <u>Total</u> 41 73 78 61 46	18.5% 37.4% 24.8% 9.6% 9.6%	M-H, Fixed, 95% CI 0.43 [0.18, 1.03] 0.40 [0.22, 0.75] 0.39 [0.17, 0.88] 0.29 [0.06, 1.32] 0.43 [0.12, 1.56]	2011 2012 2012 2012 2015	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI
Test for overall effect B Recurrence rat Study or Subgroup Pan XR Gao Z Gu ZY Hao CR Wang JY Total (95% CI)	z = 4.95 (e <u>GZFI</u> <u>Events</u> 6 11 1 7 2 3 3	P < 0.0 <u>Total</u> 44 74 78 61 46 303	Contr Events 13 27 18 7 7 7	ol <u>Total</u> 41 73 78 61 46 299	18.5% 37.4% 24.8% 9.6% 9.6%	M-H, Fixed, 95% CI 0.43 [0.18, 1.03] 0.40 [0.22, 0.75] 0.39 [0.17, 0.88] 0.29 [0.06, 1.32] 0.43 [0.12, 1.56]	2011 2012 2012 2012 2015	Favours Control Favours GZFL Risk Ratio M-H, Fixed, 95% CI

mifepristone significantly reduced serum level of estradiol (MD -20.83 pmol/L; 95% CI -34.01 to -7.65; $I^2 = 91\%$, P < .001) and progesterone (MD -0.18 mmol/L; 95% CI -0.23 to -0.12 $I^2 = 45\%$, P = .14) compared with mifepristone alone. However, there were no significant differences on serum level of FSH (MD -0.42 U/L; 95% CI -1.16 to 0.31; $I^2 = 67\%$, P = .05) and luteinizing hormone (MD -0.04 U/L; 95% CI -0.43 to 0.34; $I^2 = 0\%$, P = .63).

3.4. Adverse events

Nine trials^[17–20,23–26] reported adverse events, including gastrointestinal reaction, irregular vaginal bleeding, hot flashes, and abnormal liver function. No trial reported any serious adverse events. As shown in Figure 5, a fixed effect model meta-analysis indicated that GZFL plus mifepristone was associated with less risk of irregular vaginal bleeding (RR 0.54; 95% CI 0.32–0.91; $I^2 = 0\%$, P = .91;5 trials ^[18–20,24,26] and abnormal liver function (RR 0.45; 95% CI 0.22–0.90; $I^2 = 0\%$, P = .88; 5 trials ^[18,20,23,24]). However, there were no significant differences on the risk of gastrointestinal reaction (RR 0.45; 95% CI 0.19–1.04; $I^2 = 0\%$, P = .42; 4 trials ^[17,19,23,25]) and hot flashes events (RR 0.61; 95% CI 0.16–2.29; $I^2 = 45\%$, P = .18; 2 trials ^[17,19]).

3.5. Subgroup analyses and sensitivity analyses

We conducted the subgroup analysis on the pregnancy and recurrence rate according to the length of treatment. Results from the subgroup analysis revealed that the successful pregnancy rate was higher after 6-month treatment (RR 1.80; 95% CI 1.33–2.45) than 3-month treatment (RR 1.68; 95% CI 1.22–2.30). GZFL treatment was associated with greater reduction in recurrence of endometriosis after 6-month treatment (RR 0.40; 95% CI 0.26–0.62) than 3-month treatment subgroup (RR 0.36;

95% CI 0.13–0.95). Leave-out one trial sensitivity analyses indicated that exclusion of any individual studies each time did not alter the direction of the pooled effect sizes of pregnancy rate and recurrence rate (data not shown).

4. Discussion

The main findings of this meta-analysis indicated that GZFL plus mifepristone had additional benefits than mifepristone alone in terms of improving pregnancy rate and preventing disease recurrence among women with endometriosis. Adjuvant treatment with GZFL to mifepristone improved 74% clinical pregnancy rate and reduced 60% recurrence of endometriosis. Furthermore, GZFL as add-on therapy to mifepristone also significantly decreased serum level of estradiol and progesterone. These findings suggest that GZFL in combination with mifepristone can synergistically improve the clinical efficacy.

Suppression of sex hormone secretion may be possible therapeutic options for endometriosis. Mifepristone has been shown to inhibit the secretion of serum level of FSH, estradiol, and progesterone.^[10] In the current meta-analysis, adjuvant treatment with GZFL significantly reduced the serum level of estradiol and progesterone, which indicating suppression of estradiol and progesterone production may be correlated with the better therapeutic action. CA125 and CA199 may represent a potential biomarker of endometriosis.^[27] Mifepristone combined with GZFL significantly reduced the serum CA125 and CA199 level in women with endometriosis.^[26] In addition, preclinical studies also demonstrated its anti-inflammatory activity,^[28] anti-apoptosis,^[29] and immunological regulation effect.^[30] However, therapeutic mechanisms of GZFL remain largely unknown and should be further investigated in future studies.

A Datas dial

	G	ZFL			Control			Mean Difference				ean Differe	
study or Subgroup	Mean	SD	Total	Mear	I SD	Tota	Weigh	t IV, Random, 95	% CI	Year	IV, F	Random, 9	5% CI
in TY	118.8	10.7	32	124.8	3 18.5	32	25.69	6 -6.00 [-13.40, 1	1.40]	2010			
Shen WL	113.5	22.3	50	143.2	2 27.5	50	24.29	6 -29.70 [-39.51, -19		2013	_		
ang CQ	115.5	11.5	55	126.9	3 14.3	55	26.99	-11.40 [-16.25, -6	6.55]	2015		-	
V YL	104.44	31.71	48	143.24	1 22.7	48	23.39	6 -38.80 [-49.83, -27	7.77]	2017	_		
otal (95% CI)			185			185	100.09	-20.83 [-34.01, -7	.65]		-		
leterogeneity: Tau ² = 1	62.10; C	hi ² = 3	4.24, d	f= 3 (P	< 0.00	001); l²	= 91%				-50 -25	0	25
est for overall effect: Z	:= 3.10 (P = 0.0	02)									GZFL Fav	
Progesterone													
		GZFL			ontrol			Mean Difference				ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year		IV, Fixed	d, 95% CI	
Lin TY	0.62	0.32	32	0.61	0.37	32	10.6%	0.01 [-0.16, 0.18]	2010			-	
Shen WL	0.42	0.2	50	0.63	0.37	50	22.5%	-0.21 [-0.33, -0.09]	2013		_		
Yang CQ	0.43	0.19	55	0.62	0.2	55	57.4%	-0.19 [-0.26, -0.12]	2015				
Lv YL	0.4	0.35	48	0.63	0.53	48	9.5%	-0.23 [-0.41, -0.05]	2017				
Total (95% CI)			185			185	100.0%	-0.18 [-0.23, -0.12]			•		
784.5 2015 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995 - 1995	5.44, df	= 3 (P		; I² = 45'	%	185	100.0%	-0.18 [-0.23, -0.12]			+ +		<u>+</u>
Total (95% CI)			= 0.14)		%	185	100.0%	-0.18 [-0.23, -0.12]				0 0.25	
Total (95% CI) Heterogeneity: Chi ² =			= 0.14)		%	185	100.0%	-0.18 [-0.23, -0.12]			+ -0.5 -0.25 avours GZFL		
Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect	Z = 6.28	(P < 0	= 0.14)		%	185	100.0%	-0.18 [-0.23, -0.12]					
Total (95% CI) Heterogeneity: Chi ² =	Z = 6.28	horn	= 0.14))		185	100.0%				avours GZFL	Favours	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu	Z = 6.28	horn GZFL	= 0.14) 000001) C	ontrol			Mean Difference		F	avours GZFL Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup	Z = 6.28 alating Mean	horn GZFL SD	= 0.14) 000001 none Total) Ci Mean	ontrol SD	Total	Weight	Mean Difference IV, Random, 95% Cl		F	avours GZFL Mean	Favours	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY	Z = 6.28 alating <u>Mean</u> 5.83	horn GZFL SD 2.29	= 0.14) .00001 none <u>Total</u> 32) <u>Mean</u> 5.78	ontrol SD 2.45	Total 32	Weight 22.6%	Mean Difference <u>IV, Random, 95% Cl</u> 0.05 [-1.11, 1.21]] 201	F: ur O	avours GZFL Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ	Z = 6.28 alating <u>Mean</u> 5.83	horn GZFL SD	= 0.14) 000001 none <u>Total</u> 32 55) Mean 5.78 5.57	ontrol SD 2.45 1.84	Total	Weight	Mean Difference IV, Random, 95% Cl 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61]] 201] 201	F: 0 5	avours GZFL Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY	Z = 6.28 Ilating Mean 5.83 5.51	horn GZFL SD 2.29	= 0.14) .00001 none <u>Total</u> 32) Mean 5.78 5.57	ontrol SD 2.45	Total 32	Weight 22.6%	Mean Difference <u>IV, Random, 95% Cl</u> 0.05 [-1.11, 1.21]] 201] 201	F: 0 5	avours GZFL Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL Total (95% CI)	Z = 6.28 Ilating <u>Mean</u> 5.83 5.51 5.2	6 (P < 0 horn 6ZFL 2.29 1.76 1.34	= 0.14) 000001 none <u>Total</u> 32 55 48 135) <u>Mean</u> 5.78 5.57 6.2	ontrol SD 2.45 1.84 1.16	Total 32 55 48 135	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference IV, Random, 95% Cl 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61]] 201] 201] 201	F: 0 5	avours GZFL Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL	Z = 6.28 Ilating <u>Mean</u> 5.83 5.51 5.2	6 (P < 0 horn 6ZFL 2.29 1.76 1.34	= 0.14) 000001 none <u>Total</u> 32 55 48 135) <u>Mean</u> 5.78 5.57 6.2	ontrol SD 2.45 1.84 1.16	Total 32 55 48 135	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference <u>IV. Random, 95% Cl</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50]] 201] 201] 201	F: 0 5	Mean	Favours of Difference	control
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL Total (95% CI)	Z = 6.28 Ilating <u>Mean</u> 5.83 5.51 5.2 = 0.28; C	born GZFL <u>SD</u> 1.76 1.34 chi ² = 6	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df=) <u>Mean</u> 5.78 5.57 6.2	ontrol SD 2.45 1.84 1.16	Total 32 55 48 135	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference <u>IV. Random, 95% Cl</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50]] 201] 201] 201	F: 0 5 7	avours GZFL Mean	Difference	1
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL Total (95% CI) Heterogeneity: Tau ² :	E Z = 6.28 Mean 5.83 5.51 5.2 = 0.28; C t Z = 1.13	b (P < 0 horm GZFL 2.29 1.76 1.34 hi ² = 6 3 (P = 0	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df=) <u>Mean</u> 5.78 5.57 6.2	ontrol SD 2.45 1.84 1.16	Total 32 55 48 135	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference <u>IV. Random, 95% Cl</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50]] 201] 201] 201	F: 0 5 7	Mean Mean M. Rand	Difference	1
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL Total (95% CI) Heterogeneity: Tau ² : Test for overall effect	: Z = 6.28 alating <u>Mean</u> 5.83 5.51 5.2 = 0.28; C t Z = 1.13 normor	P < 0 horm GZFL SD 2.29 1.76 1.34 $hi^2 = 6.3$ P = 0 he	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df=) <u>Mean</u> 5.78 5.57 6.2 = 2 (P =	ontrol SD 2.45 1.84 1.16 0.05);	Total 32 55 48 135	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference IV, Random, 95% C 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50] -0.42 [-1.16, 0.31]] 201] 201] 201	F: 0 5 7	Mean Mean M. Rand 	Favours of Difference dom, 95% (0 1 L Favours	1
Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Study or Subgroup Lin TY Yang CQ Lv YL Total (95% Cl) Heterogeneity: Tau ² Test for overall effect C Luteinizing h	: Z = 6.28 alating <u>Mean</u> 5.83 5.51 5.2 = 0.28; C : Z = 1.13 normor	P < 0 horm GZFL 2.29 1.76 1.34 $hi^2 = 6$ 3 (P = 0) ne GZFL	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df= 0.26)) <u>Mean</u> 5.78 5.57 6.2 = 2 (P =	0.05);	Total 32 55 48 135 ₽ = 679	Weight 22.6% 36.0% 41.4% 100.0%	Mean Difference <u>IV. Random, 95% CI</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50] -0.42 [-1.16, 0.31] Mean Difference] 201] 201] 201	F:	Mean Mean M. Ram -2 -1 Favours GZF ean Difference	Favours of Difference dom, 95% (0 1 L Favours	1
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Lin TY Yang CQ Lv YL Total (95% CI) Heterogeneity: Tau ² Test for overall effect D Luteinizing h Study or Subgroup	: Z = 6.28 Mean 5.83 5.51 5.2 = 0.28; C t Z = 1.13 Mean	P < 0 horm GZFL 2.29 1.76 1.34 $hi^2 = 6$ 3 (P = 0) GZFL SD	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df= 0.26) <u>Total</u>) <u>Mean</u> 5.78 5.57 6.2 = 2 (P = C <u>Mean</u>	ontrol SD 2.45 1.84 1.16 0.05); ontrol SD	Total 32 55 48 135 1 ² = 679 Total	Weight 22.6% 36.0% 41.4% 100.0% %	Mean Difference <u>IV. Random, 95% CI</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50] -0.42 [-1.16, 0.31] Mean Difference <u>IV. Fixed, 95% CI</u>] 201] 201] 201	F:	Mean Mean M. Rand 	Favours of Difference dom, 95% (0 1 L Favours	12
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Lin TY Yang CQ Lv YL Total (95% CI) Heterogeneity: Tau ² : Test for overall effect C Luteinizing h Study or Subgroup Lin TY	: Z = 6.28 Ilating <u>Mean</u> 5.83 5.51 5.2 = 0.28; C t Z = 1.13 normor <u>Mean</u> 5.97	P < 0 horm GZFL SD 2.29 1.76 1.34 $hi^2 = 6$ 3 (P = 0) e GZFL SD I.35	= 0.14) 00001 none <u>Total</u> 32 55 48 135 12, df= 0.26) <u>Total</u> 32) <u>Mean</u> 5.78 5.57 6.2 = 2 (P = <u>C</u> <u>Mean</u> 6.04	ontrol SD 2.45 1.84 1.16 0.05); ontrol SD 1.77	<u>Total</u> 32 55 48 135 ₽ = 679 <u>Total</u> 32	Weight 22.6% 36.0% 41.4% 100.0% %	Mean Difference <u>IV. Random, 95% CI</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50] -0.42 [-1.16, 0.31] Mean Difference <u>IV. Fixed, 95% CI</u> -0.07 [-0.91, 0.77]] 201] 201] 201	F:	Mean Mean M. Ram -2 -1 Favours GZF ean Difference	Favours of Difference dom, 95% (0 1 L Favours	1
Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C Follicle-stimu Lin TY Yang CQ Lv YL Total (95% CI) Heterogeneity: Tau ² Test for overall effect C Luteinizing h	Z = 6.28 Mean 5.83 5.51 5.2 = 0.28; C z = 1.13 Mean 5.97 5.96	P < 0 horm GZFL 2.29 1.76 1.34 $hi^2 = 6$ 3 (P = 0) GZFL SD	= 0.14) 000001 none <u>Total</u> 32 55 48 135 12, df= 0.26) <u>Total</u>) <u>Mean</u> 5.78 5.57 6.2 = 2 (P = <u>C</u> <u>Mean</u> 6.04 6.19	ontrol SD 2.45 1.84 1.16 0.05); ontrol SD 1.77	Total 32 55 48 135 1 ² = 679 Total	Weight 22.6% 36.0% 41.4% 100.0% %	Mean Difference <u>IV. Random, 95% CI</u> 0.05 [-1.11, 1.21] -0.06 [-0.73, 0.61] -1.00 [-1.50, -0.50] -0.42 [-1.16, 0.31] Mean Difference <u>IV. Fixed, 95% CI</u> -0.07 [-0.91, 0.77] -0.23 [-0.82, 0.36]] 201] 201] 201	F:	Mean Mean M. Ram -2 -1 Favours GZF ean Difference	Favours of Difference dom, 95% (0 1 L Favours	1

Figure 4. Forest plots showing comparison of serum level of estradiol (A), progesterone (B), follicle-stimulating hormone (C), and luteinizing hormone (D) comparing GZFL plus mifepristone to mifepristone alone treatment.

Another concern is whether add-on therapy using GZFL maybe increases the adverse events. Irregular vaginal bleeding, hot flushes, nausea, vomiting, and impaired liver function was the most common adverse effect of mifepristone.^[31] In this metaanalysis, lower risk of irregular vaginal bleeding and abnormal liver function was observed in women with GZFL plus mifepristone therapy than mifepristone alone, suggesting GZFL could decrease mifepristone-related adverse effects. Moreover, GZFL as add-on therapy to mifepristone did not increase hot flushes and gastrointestinal discomfort. Post-marketing surveillance on GZFL based on literature showed that mild gastrointestinal system damage was its most common adverse effects and no serious adverse events were reported.^[32]

When taken the length of GZFL treatment into account, longterm (6 months) treatment with GZFL could achieve greater reduction in recurrence rate and improvement in clinical pregnancy rate. Apart from mifepristone, GZFL also combined with leuprorelin, triptorelin, gestrinone, or danazol to treat endometriosis. The efficacy and safety of GZFL as an add-on therapy to these agents should be systematically evaluated.

This study had several weaknesses. First, methodological flaws of the included trials were a major concern. Most trials did not clearly report the method of randomization, allocation concealment, and sample sizes estimation. Second, TCM pattern differentiation was not taken into the diagnostic procedure, which could have resulted in potential selection bias of patients. Third, substantial heterogeneity was found in pooling serum hormone level (I^2 up to 91%). Different duration of treatment, patients' characteristics, and methodological quality may contribute to the significant heterogeneity. Fourth, lack of information on stage in most trials was another weakness. Variations of stages could have influenced the pooling result for

	GZFI	L	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Vaginal bleeding								
Lin TY	6	32	9	32	11.1%	0.67 [0.27, 1.66]	2010	
Pan XR	1	44	3	41	3.8%	0.31 [0.03, 2.87]	2011	
Gu ZY	6	78	9	78	11.1%	0.67 [0.25, 1.78]	2012	
Yang CQ	4	55	8	55	9.9%	0.50 [0.16, 1.56]	2015	
LV YL	2	48	6	48	7.4%	0.33 [0.07, 1.57]	2017	
Subtotal (95% CI)		257		254	43.5%	0.54 [0.32, 0.91]		
Total events	19		35					ee
Heterogeneity: Chi ² =	1.01, df=	4 (P =	0.91); 12=	= 0%				
Test for overall effect:								
Gastrointestinal read	tion							
Lu CH	1	40	0	40	0.6%	3.00 [0.13, 71.51]	2007	
Pan XR	2	44	2	41	2.6%	0.93 [0.14, 6.31]		
Hao CR	3	61	12	61	14.9%	0.25 [0.07, 0.84]		
Wang JY	1	46	2	46	2.5%	0.50 [0.05, 5.32]		
Subtotal (95% CI)	1	191	-	188	20.5%	0.45 [0.19, 1.04]	2011	•
Total events	7		16		201010	0.10 [0.10, 101]		
Heterogeneity: Chi ² =	Sector Sector	2 /P -	Contraction of the second	- 0%				
Test for overall effect:	the second s			- 0.0				
Hot flashes								
Lu CH	0	40	3	40	4.3%	0.14 [0.01, 2.68]	2007	
Pan XR	3	44	2	41	2.6%	1.40 [0.25, 7.95]		
Subtotal (95% CI)	3	84	2	81	6.9%	0.61 [0.16, 2.29]	2011	
Total events	3	04	5	01	0.970	0.01 [0.10, 2.29]		
	1.000	1 /0 -		450				
Heterogeneity: Chi ² = Test for overall effect:	and the second se			- 40%				
Abnormal liver funct	ion							
		22	5	22	0.00	0 00 10 40 0 001	204.0	
Lin TY	3	32	5	32	6.2%	0.60 [0.16, 2.30]		
Gu ZY	3	78	5	78	6.2%	0.60 [0.15, 2.42]		
Hao CR	1	61	5	61	6.2%	0.20 [0.02, 1.66]		
Yang CQ	3	55	6	55	7.4%	0.50 [0.13, 1.90]		
LVYL	0	48	2	48	3.1%	0.20 [0.01, 4.06]	2017	
Subtotal (95% CI)	102/12/8-11	274		274	29.1%	0.45 [0.22, 0.90]		-
Total events	10		23					
Heterogeneity: Chi ² =				= 0%				
Test for overall effect:	Z= 2.24	(P = 0.0	12)					
Total (95% CI)		806		797	100.0%	0.50 [0.35, 0.72]		•
Total events	39		79					3
Heterogeneity: Chi ² =	7.30, df=	15 (P	= 0.95); *	= 0%				0.005 0.1 1 10 20
	Z= 3.77							Favours GZFL Favours control

Figure 5. Forest plots showing comparison of adverse events comparing GZFL plus mifepristone to mifepristone alone treatment.

recurrence of endometriosis.^[33] Fifth, a valid pain scale was not used to assess dysmenorrhea and pelvic pain. However, the pain scale was subjective, which could have led to measurement bias. Finally, the length of follow-up maybe not long enough to observe the recurrence of endometriosis and up to 5-year followup duration should be carried out.^[34]

5. Conclusions

This meta-analysis indicates that GZFL as adjuvant therapy to mifepristone appears to have additional benefits in prevention of recurrence of endometriosis and improvement of pregnancy among women with endometriosis. Therefore, GZFL may be a candidate as an add-on therapy for management of endometriosis. However, future well-designed trials are required to confirm these findings because of methodological flaws in the analyzed trials.

Author contributions

Conceptualization: Fei Wang. Data curation: Wenbin Meng, Na Ta. Formal analysis: Wenbin Meng, Na Ta. Investigation: Na Ta. Methodology: Wenbin Meng, Fei Wang. Project administration: Fei Wang. Resources: Wenbin Meng, Na Ta.

Supervision: Fei Wang.

Validation: Fei Wang.

Writing - original draft: Wenbin Meng.

Writing – review & editing: Na Ta.

Fei Wang orcid: 0000-0001-8568-9027.

References

- [1] Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99.
- [2] Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400–12.
- [3] Li J, Liu R, Tang S, et al. Impact of endometriosis on risk of ovarian, endometrial and cervical cancers: a meta-analysis. Arch Gynecol Obstet 2019;299:35–46.
- [4] Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs 2018;78:995– 1012.
- [5] Bozdag G. Recurrence of endometriosis: risk factors, mechanisms and biomarkers. Women's Health 2015;11:693–9.
- [6] Yeung PJr. The laparoscopic management of endometriosis in patients with pelvic pain. Obstet Gynecol Clin North Am 2014;41:371–83.
- [7] Han YF, Hou LH, Zhou YJ, et al. A survey of TCM treatment for endometriosis. J Tradit Chin Med 2009;29:64–70.
- [8] Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23–8.
- [9] Kettel LM, Murphy AA, Morales AJ, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151–6.
- [10] Zhang YX. Effect of mifepristone in the different treatments of endometriosis. Clin Exp Obstet Gynecol 2016;43:350–3.
- [11] Guo SW, Liu M, Shen F, et al. Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women's Health 2011;7:51–70.
- [12] Su ZZ, Li N, Cao L, et al. Main progress on studies of pharmacological activities and clinical applications of Guizhi Fuling capsule. Zhongguo Zhong Yao Za Zhi 2015;40:989–92.
- [13] Li XX, Xu X, Ma HX, et al. Clinical and experimental research progress on Guizhi Fuling Pill of classical herbal formula. Drug Eval Res 2018;41:1724–9.
- [14] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34.
- [15] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
- [16] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

- [17] Lu CH. Research about the efficacy of Guizhi Fulin capsule- mifepristone combination therapy for endometriosis. Mod Med J China 2007;9:50–1.
- [18] Lin TY. Clinical observation of the treatment effect of Guizhi Fuling capsule combined with mifepristone on endometriosis. Hebei Med 2010;16:578–60.
- [19] Pan XR. Effect of mifepristone combined with Guizhi Fuling capsule on endometriosis. China Prac Med 2011;6:136–7.
- [20] Gu ZY. Clinical efficacy of mifepristone combined with Guizhi Fuling capsule in the treatment of endometriosis. St Rait Pharmaceutical J 2012;24:193–5.
- [21] Gao Z. Effect of drug therapy for endometriosis after laparoscopic surgery. Maternal Child Health Care China 2012;27:3663–4.
- [22] Shen WL. Clinical effects of the Guizhi Fuling capsule plus mifepristone on the serum hormone in treating endometriosis. Clin J Chin Med 2013;5:28–9.
- [23] Hao CR. Clinical observation of consolidation therapy of Guizhi Fuling capsule and mifepristone after laparoscopic surgery for endometriosis. Women's Health Res 2015;22:220–1.
- [24] Yang CQ, Wang XH, Jiang YL. Curative effect analysis of Guizhi Fuling capsule combined with mifepristone in the treatment of endometriosis. Hebei Med J 2015;37:194–5.
- [25] Wang JY. Effect of mifepristone combined with Guizhi Fuling capsule on endometriosis. J Huaihai Med 2017;35:344–5.
- [26] Lv YL, Li J, Han L. Effect of mifepristone combined with Guizhi Fuling capsule on the serum CA125, CA199 and sex hormone levels in endometriosis patients. World Clin Drugs 2017;38:475–7. 482.
- [27] Nisenblat V, Bossuyt PM, Shaikh R, et al. Blood biomarkers for the noninvasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016; CD012179.
- [28] Jeong SJ, Lim HS, Seo CS, et al. Anti-inflammatory actions of herbal formula Gyejibokryeong-hwan regulated by inhibiting chemokine production and STAT1 activation in HaCaT cells. Biol Pharm Bull 2015;38:425–34.
- [29] Hu C, Wang Z, Pang Z, et al. Guizhi fuling capsule, an ancient Chinese formula, attenuates endometriosis in rats via induction of apoptosis. Climacteric 2014;17:410–6.
- [30] Ji X, Gao J, Cai X, et al. Immunological regulation of Chinese herb Guizhi Fuling Capsule on rat endometriosis model. J Ethnopharmacol 2011;134:624–9.
- [31] Jiang J, Lu J, Wu R. Mifepristone following conservative surgery in the treatment of endometriosis. Zhonghua Fu Chan Ke Za Zhi 2001; 36:717–20.
- [32] Wang GQ, Gao Y, Liu FM, et al. Post-marketing surveillance on Guizhi Fuling Jiaonang based on literature review. Zhongguo Zhong Yao Za Zhi 2018;43:820–32.
- [33] Kikuchi I, Takeuchi H, Kitade M, et al. Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand 2006;85:1120–4.
- [34] Guo SW. Recurrence of endometriosis and its control. Human Reprod Update 2009;15:441–61.